Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis
Open Access
- 21 August 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 124 (8), 1296-1299
- https://doi.org/10.1182/blood-2014-04-566521
Abstract
Key Points Occult marrow disease is demonstrable in 68% of patients with solitary plasmacytoma of bone and is predictive of progression. Trials of adjuvant systemic therapy are warranted in high-risk patients.Keywords
This publication has 16 references indexed in Scilit:
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyJournal of Clinical Oncology, 2013
- Trends and outcomes of modern staging of solitary plasmacytoma of boneAmerican Journal of Hematology, 2012
- Solitary plasmacytomasCancer, 2011
- Solitary PlasmacytomaAmerican Journal of Clinical Oncology, 2009
- Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group‐Sarcoma Working PartyAmerican Journal of Hematology, 2008
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersHaematologica, 2008
- Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006
- Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network studyBMC Cancer, 2006
- Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patientsInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationBlood, 2002